Norditropin Daily denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## UnitedHealthcare Medical-Necessity Denials for Norditropin Daily: The Real Mechanics

A UnitedHealthcare medical-necessity denial on Norditropin (daily somatropin) is rarely a flat "not covered" — it is almost always a failure to satisfy a specific clause inside the Commercial Medical Benefit Drug Policy: Human Growth Hormone – Somatropin. The reviewer (OptumRx clinical pharmacist on the Commercial benefit, or Optum Specialty for HMSA-style carve-outs) is matching your submission against a checklist: diagnosis class, biochemical confirmation, growth velocity SDS, and the "essential vs. non-essential" determination that controls whether benefit caps and supply limits engage.

Why the denial fires. UHC's policy splits GH therapy into essential (chronic-disease replacement — Congenital GHD, Pediatric GHD, Adult GHD, Prader-Willi, Transition Phase) and non-essential (SGA without catch-up, ISS). For Adult GHD, the most common defect is a missing or wrong-threshold provocative test — UHC's policy names the Insulin Tolerance Test (ITT) with peak GH < 5 ng/mL as the test of choice. Glucagon stim or macimorelin results without documented threshold logic get rejected. For Pediatric GHD and ISS, denials cluster around inadequate height SDS documentation (< –2.25 for ISS), missing bone-age films, or absent endocrinologist coordination — UHC explicitly requires an endocrinologist to manage therapy.

The procedural lever that matters. Norditropin daily on a Commercial UHC plan is adjudicated through OptumRx PA via the SureScripts/CoverMyMeds channel when self-administered, or through the Medical Benefit Drug PA queue when billed buy-and-bill (HCPCS J2941). Submitting to the wrong queue produces a "missing information" denial that looks like medical necessity. Verify the benefit type on the back of the card before appealing.

Regulatory backstop. Under 29 CFR §2560.503-1(g), UHC must disclose the specific policy version and clinical rationale on the denial letter — demand the exact policy effective date if the EOB cites only "medical necessity." If the plan is ERISA-governed and the denial reads as a blanket experimental-style refusal, Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) controls: the insurer carries the burden of producing the clinical evidence supporting denial, not the patient. For Medicare Advantage (UHC AARP plans), 42 CFR §422.566 preserves your right to an expedited 72-hour reconsideration when delay threatens function — useful for pediatric patients losing growth-plate window.

Tactical tip. Re-submit with: (1) the ITT or glucagon-stim raw lab report with peak GH value circled, (2) IGF-1 and IGFBP-3 z-scores, (3) bone-age radiograph interpretation, (4) height SDS calculation showing < –2.25 if ISS, and (5) a one-page endocrinologist letter explicitly invoking the UHC policy's "essential use" language to defeat the benefit cap. If the second-level appeal fails, file an IRO external review within 4 months under ACA §2719 — UHC overturns roughly a third of GH cases at IRO when the ITT threshold is clearly documented.